Literature DB >> 3899240

Efficacy and safety of low-molecular-weight heparin (CY216) in preventing postoperative venous thrombo-embolism: a co-operative study.

V V Kakkar, W J Murray.   

Abstract

The efficacy and safety of a low-molecular-weight (LMW) heparin fraction in preventing postoperative venous thrombo-embolism, was assessed in a double blind, randomly allocated trial, and in an 'open' study. Of 395 patients included in the double blind trial, 199 received unfractionated (UF) calcium heparin, and 196 the LMW heparin fraction. The data were analysed on an 'intention to treat' basis. The two groups were well matched for risk factors which could predispose to the development of venous thrombosis. Fifteen (7.5 per cent) of one hundred and ninety-nine patients receiving UF heparin, and five (2.5 per cent) of one hundred and ninety-six patients in the LMW heparin group developed DVT (P less than 0.05). There was no significant difference between the two groups in terms of excessive incisional or total blood loss during surgery, postoperative drainage or wound haematoma formation. Of 910 patients included in the 'open' study who received a single injection of LMW heparin every day, 30 (3.2 per cent) died during the postoperative period; in none of the autopsied patients were pulmonary emboli detected. Thirty-one (3.4 per cent) patients developed isotopic DVT; twenty-seven (2.9 per cent) were receiving prophylaxis at the time the DVT was diagnosed. Thirty-six (3.9 per cent) patients developed wound haematoma; twenty-five (12.4 per cent) of those were in the two hundred and one undergoing surgery for gynaecological conditions, and eleven (1.5 per cent) in the seven hundred and nine patients having general abdominal surgery. This difference is statistically significant (P less than 0.001). The results of a double blind trial indicate that a single daily injection of 1850 APTT units (7500 antifactor Xa units) of a LMW heparin is more effective than 10 000 APTT units of commercially available UF heparin in preventing postoperative DVT. The findings of the 'open' study suggest that this regimen also provides an effective prophylaxis against post-operative major pulmonary embolism.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3899240     DOI: 10.1002/bjs.1800721006

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  26 in total

Review 1.  New thrombolytics, anticoagulants, and platelet antagonists: the future of clinical practice.

Authors:  R C Becker
Journal:  J Thromb Thrombolysis       Date:  1999-04       Impact factor: 2.300

2.  Adjunctive Pharmacologic Treatment: Focus on the Development of Low Molecular Weight Heparins.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1997       Impact factor: 2.300

Review 3.  Formulary management of low molecular weight heparins.

Authors:  W E Wade; B C Martin; J A Kotzan; W J Spruill; M A Chisoholm; M Perri
Journal:  Pharmacoeconomics       Date:  2000-01       Impact factor: 4.981

Review 4.  Nadroparin calcium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders.

Authors:  R Davis; D Faulds
Journal:  Drugs Aging       Date:  1997-04       Impact factor: 3.923

Review 5.  Adverse skin reactions to low molecular weight heparins: frequency, management and prevention.

Authors:  R Wütschert; P Piletta; H Bounameaux
Journal:  Drug Saf       Date:  1999-06       Impact factor: 5.606

Review 6.  Prevention of venous thromboembolism in gynecologic oncology surgery.

Authors:  Emma L Barber; Daniel L Clarke-Pearson
Journal:  Gynecol Oncol       Date:  2016-11-25       Impact factor: 5.482

Review 7.  The pathogenesis and prevention of thromboembolic complications in patients undergoing total hip replacement.

Authors:  D K Potyk; H J Tabbarah
Journal:  J Gen Intern Med       Date:  1993-04       Impact factor: 5.128

8.  [Prevention of thromboembolism in trauma surgery by dose adjustment of low molecular weight heparin depending on levels of TAT and D-dimer].

Authors:  A Mayer; M Hansen; D Peetz; G Hafner; N Vogel; W Prellwitz; P M Rommens
Journal:  Unfallchirurg       Date:  2003-12       Impact factor: 1.000

9.  Low molecular weight heparin in prevention of perioperative thrombosis.

Authors:  A Leizorovicz; M C Haugh; F R Chapuis; M M Samama; J P Boissel
Journal:  BMJ       Date:  1992-10-17

Review 10.  Nadroparin calcium. A review of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disorders.

Authors:  L B Barradell; M M Buckley
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.